The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a treatment for people with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) — the second most common form of skin cancer — that is not curable by surgery or radiation therapy. The decision was based on data from a Phase 2 trial called KEYNOTE-629 (NCT03284424), in which Keytruda was found to reduce tumor burden in a meaningful proportion of patients. It also helped…
You must be logged in to read/download the full post.
The post FDA Approves Keytruda for Advanced Squamous Cell Skin Cancer appeared first on BioNewsFeeds.